Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice

Brain Research Bulletin

Volumn 88, Issue 2-3, 2012, Pages 104-112

  Bayram Weston, Zubeyde ^a   Jones, Lesley ^a   Dunnett, Stephen B ^a   Brooks, Simon P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aggregations; Huntington's disease; Inclusions; R6 1; Transgenic mice; Transmission electron microscope (TEM)

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN;

AGE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELL DENSITY; CELL LOSS; CELL NUCLEUS INCLUSION BODY; CELL NUCLEUS MEMBRANE; CELL STRUCTURE; CELL VACUOLE; CEREBELLUM; CORPUS STRIATUM; CYTOPLASM; ELECTRON MICROSCOPY; FEMALE; GLOBUS PALLIDUS; HETEROZYGOTE; HIPPOCAMPUS; HISTOPATHOLOGY; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MALE; MICROSCOPY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; THALAMUS; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; NEURONS;

EID: 84860837080     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.07.009     Document Type: Article

References (84)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 1946, 239-247.
2. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
3. Bates G.P., Harper P.S., Jones L. Huntington's Disease 2002, Oxford University Press. G.P. Bates, P.S. Harper, L. Jones (Eds.).
4. Bates G.P., Mangiarini L., Mahal A., Davies S.W. Transgenic models of Huntington's disease. Hum. Mol. Genet. 1997, 6:1633-1637.
5. Q92/Q92 Huntington's disease mice. Brain Res. Bull. 2012, 88:171-181.
6. Bayram-Weston Z., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 transgenic mice. Brain Res. Bull. 2012, 88:137-147.
7. Bayram-Weston Z., Torres E.M., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh(CAG)150 Huntington's disease knock-in mouse. Brain Res. Bull. 2012, 88:189-198.
8. Bolivar V.J., Manley K., Messer A. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Res. 2004, 1005:29-35.
9. Bolivar V.J., Walters S.R., Phoenix J.L. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav. Brain Res. 2007, 176:21-26.
10. Bowen I.D. Apoptosis or programmed cell death?. Cell Biol. Int. 1993, 17:365-380.
11. Bredesen D.E., Rao R.V., Mehlen P. Cell death in the nervous system. Nature 2006, 443:796-802.
12. Brooks S.P., Janghra N., Workman V.L., Bayram-Weston Z., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Res. Bull. 2011, 10.1016/j.brainresbull.2011.01.010.
13. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19:3248-3257.
14. Damiano M., Galvan L., Deglon N., Brouillet E. Mitochondria in Huntington's disease. Biochim. Biophys. Acta 2010, 1802:52-61.
15. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
16. Deschepper M., Hoogendoorn B., Brooks S., Dunnett S.B., Jones L. Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes. Brain Res. Bull. 2011, 10.1016/j.brainresbull.2011.01.012.
17. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
18. Galatioto S. Immunohistochemical findings in Huntington's Chorea: report of 9 cases. Pathologica 1996, 88:491-499.
19. Georgiou N., Bradshaw J.L., Chiu E., Tudor A., O'Gorman L., Phillips J.G. Differential clinical and motor control function in a pair of monozygotic twins with Huntington's disease. Mov. Disord. 1999, 14:320-325.
20. Gorman A.M. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J. Cell Mol. Med. 2008, 12:2263-2280.
21. Gourfinkel-An I., Cancel G., Duyckaerts C., Faucheux B., Hauw J.J., Trottier Y., Brice A., Agid Y., Hirsch E.C. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport 1998, 9:1823-1826.
22. Graveland G.A., Williams R.S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985, 227:770-773.
23. Grote H.E., Bull N.D., Howard M.L., van Dellen A., Blakemore C., Bartlett P.F., Hannan A.J. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci. 2005, 22:2081-2088.
24. Gusella J.F., MacDonald M.E. Huntington's disease: the case for genetic modifiers. Genome Med. 2009, 1:80.
25. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
26. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 2001, 14:1492-1504.
27. Heng M.Y., Duong D.K., Albin R.L., Tallaksen-Greene S.J., Hunter J.M., Lesort M.J., Osmand A., Paulson H.L., Detloff P.J. Early autophagic response in a novel knock-in model of Huntington disease. Hum. Mol. Genet. 2010, 19:3702-3720.
28. Herishanu Y.O., Parvari R., Pollack Y., Shelef I., Marom B., Martino T., Cannella M., Squitieri F. Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?. J. Neurol. Sci. 2009, 277:143-146.
29. Ho A.K., Sahakian B.J., Brown R.G., Barker R.A., Hodges J.R., Ane M.N., Snowden J., Thompson J., Esmonde T., Gentry R., Moore J.W., Bodner T. Profile of cognitive progression in early Huntington's disease. Neurology 2003, 61:1702-1706.
30. Ho L.W., Carmichael J., Swartz J., Wyttenbach A., Rankin J., Rubinsztein D.C. The molecular biology of Huntington's disease. Psychol. Med. 2001, 31:3-14.
31. Hodges A., Hughes G., Brooks S., Elliston L., Holmans P., Dunnett S.B., Jones L. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav. 2008, 7:288-299.
32. Jeste D.V., Barban L., Parisi J. Reduced Purkinje cell density in Huntington's disease. Exp. Neurol. 1984, 85:78-86.
33. Kerr J.F.R., Gobe G.G., Winterford C.M., Harmon B.V. Anatomical methods in cell death. Methods in Cell Biology 1995, 1-27. Academic Press Inc., San Diego. L.M. Schwartz, B.A. Osborno (Eds.).
34. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26:239-257.
35. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
36. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 2008, 7:1013-1030.
37. Kirkwood S.C., Siemers E., Hodes M.E., Conneally P.M., Christian J.C., Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J. Neurol. Neurosurg. Psychiatry 2000, 69:773-779.
38. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(Pt 7):1329-1341.
39. Lazic S.E., Grote H.E., Blakemore C., Hannan A.J., van Dellen A., Phillips W., Barker R.A. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur. J. Neurosci. 2006, 23:1829-1838.
40. Legleiter J., Lotz G.P., Miller J., Ko J., Ng C., Williams G.L., Finkbeiner S., Patterson P.H., Muchowski P.J. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J. Biol. Chem. 2009, 284:21647-21658.
41. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation-a longitudinal follow-up study. J. Neurol. 2004, 251:935-942.
42. Li H., Wyman T., Yu Z.X., Li S.H., Li X.J. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum. Mol. Genet. 2003, 12:2021-2030.
43. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
44. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. 1999, 19:10428-10437.
45. Lloret A., Dragileva E., Teed A., Espinola J., Fossale E., Gillis T., Lopez E., Myers R.H., MacDonald M.E., Wheeler V.C. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum. Mol. Genet. 2006, 15:2015-2024.
46. Maat-Schieman M.L., Dorsman J.C., Smoor M.A., Siesling S., Van Duinen S.G., Verschuuren J.J., den Dunnen J.T., van Ommen G.J., Roos R.A. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J. Neuropathol. Exp. Neurol. 1999, 58:129-137.
47. Maat-Schieman M., Roos R., Losekoot M., Dorsman J., Welling-Graafland C., Hegeman-Kleinn I., Broeyer F., Breuning M., van Duinen S. Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease. Brain Pathol. 2007, 17:31-37.
48. Majno G., Joris I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am. J. Pathol. 1995, 146:3-15.
49. Mangiarini L., Sathasivam K., Mahal A., Mott R., Seller M., Bates G.P. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat. Genet. 1997, 15:197-200.
50. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
51. Martinez-Vicente M., Talloczy Z., Wong E., Tang G., Koga H., Kaushik S., de Vries R., Arias E., Harris S., Sulzer D., Cuervo A.M. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat. Neurosci. 2010, 13:567-576.
52. Menalled L.B., Sison J.D., Wu Y., Olivieri M., Li X.J., Li H., Zeitlin S., Chesselet M.F. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 2002, 22:8266-8276.
53. Miller J., Arrasate M., Shaby B.A., Mitra S., Masliah E., Finkbeiner S. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J. Neurosci. 2010, 30:10541-10550.
54. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum. Mol. Genet. 2006, 15:1690-1703.
55. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L., Skepper J.N., Wight J.M. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
56. Naver B., Stub C., Moller M., Fenger K., Hansen A.K., Hasholt L., Sorensen S.A. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
57. Nithianantharajah J., Barkus C., Murphy M., Hannan A.J. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol. Dis. 2008, 29:490-504.
58. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego, CA. 2nd ed.
59. Petersen A., Chase K., Puschban Z., DiFiglia M., Brundin P., Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 2002, 175:297-300.
60. Petersen A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W.T., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 2002, 11:134-146.
61. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
62. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O., Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 1998, 20:198-202.
63. Rodda R.A. Cerebellar atrophy in Huntington's disease. J. Neurol. Sci. 1981, 50:147-157.
64. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
65. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?. Neuron 1997, 19:1147-1150.
66. Ross C.A., Becher M.W., Colomer V., Engelender S., Wood J.D., Sharp A.H. Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. Brain Pathol. 1997, 7:1003-1016.
67. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
68. Rubinsztein D.C., Leggo J., Coles R., Almqvist E., Biancalana V., Cassiman J.J., Chotai K., Connarty M., Crauford D., Curtis A., Curtis D., Davidson M.J., Differ A.M., Dode C., Dodge A., Frontali M., Ranen N.G., Stine O.C., Sherr M., Abbott M.H., Franz M.L., Graham C.A., Harper P.S., Hedreen J.C., Hayden M.R. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am. J. Hum. Genet. 1996, 59:16-22.
69. Rubinsztein D.C., Wyttenbach A., Rankin J. Intracellular inclusions pathological markers in diseases caused by expanded polyglutamine tracts?. J. Med. Genet. 1999, 36:265-270.
70. Ruocco H.H., Lopes-Cendes I., Li L.M., Santos-Silva M., Cendes F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz. J. Med. Biol. Res. 2006, 39:1129-1136.
71. Sapp E., Schwarz C., Chase K., Bhide P.G., Young A.B., Penney J., Vonsattel J.P., Aronin N., DiFiglia M. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 1997, 42:604-612.
72. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
73. Shirendeb U., Reddy A.P., Manczak M., Calkins M.J., Mao P., Tagle D.A., Hemachandra R.P. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011, 20:1438-1455.
74. Sisodia S.S. Nuclear inclusions in glutamine repeat disorders: are they pernicious coincidental, or beneficial?. Cell 1998, 95:1-4.
75. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490:354-370.
76. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
77. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8093-8097.
78. van der Borght K., Brundin P. Reduced expression of PSA-NCAM in the hippocampus and piriform cortex of the R6/1 and R6/2 mouse models of Huntington's disease. Exp. Neurol. 2007, 204:473-478.
79. Van Raamsdonk J.M., Metzler M., Slow E., Pearson J., Schwab C., Carroll J., Graham R.K., Leavitt B.R., Hayden M.R. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 2007, 26:189-200.
80. Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:3823-3835.
81. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:365-375.
82. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
83. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 2000, 9:503-513.
84. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.